ReviewRSC advances2019
Nanozyme-based catalytic theranostics.
Review in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 175 citations in OpenAlex.
- Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.International journal of pharmaceutics: X · 2026Review
- An Injectable Magneto-Responsive Periosteum Reprograms Neutrophil Extracellular Trap Formation for Osteomyelitis Treatment.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A Biomimetic Copper-Caffeic Acid Nanozyme Activates Cuproptosis and Pyroptosis by Mimicking the Neutrophil Enzymatic Cascade.Advanced healthcare materials · 2026Article
- A manganese-luteolin co-loaded antioxidant hydrogel for synergistic alleviation of oxidative stress and immunomodulation in intervertebral disc degeneration.Materials today. Bio · 2026Article
- Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.Discover nano · 2026Review
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- Calcium peroxide nanoplatform-mediated cancer immunotherapy enhancement: current advances and perspective.PeerJ · 2026Review
- Cerium-based nanozymes for chemodynamic therapy: tumor microenvironment-responsive mechanisms and applications.Frontiers in chemistry · 2026Review
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
- Nanozyme-driven multifunctional dressings: moving beyond enzyme-like catalysis in chronic wound treatment.Military Medical Research · 2025Review
- Preparation of Iron oxide/palladium nanoparticles modified with carbon quantum dots (Pd@CQD@FeScientific reports · 2025Article
- Immunomodulatory Effects ofAntioxidants (Basel, Switzerland) · 2025Article
- Self-assembled antioxidant enzyme-mimicking hydrogel: Targeting oxidative stress and macrophage organization for improving degenerated intervertebral discs.Materials today. Bio · 2025Article
- Removing Barriers to Tumor 'Oxygenation': Depleting Glutathione Nanozymes in Cancer Therapy.International journal of nanomedicine · 2025Review
- The recent research progress in the application of the nanozyme-hydrogel composite system for drug delivery.Drug delivery · 2024Review
- Emerging Nanomaterials as Versatile Nanozymes: A New Dimension in Biomedical Research.Topics in current chemistry (Cham) · 2024Review
- Superoxide dismutase and neurological disorders.IBRO neuroscience reports · 2024Review
- Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy.Nano-micro letters · 2024Review
- Gadolinium Doping Modulates the Enzyme-like Activity and Radical-Scavenging Properties of CeONanomaterials (Basel, Switzerland) · 2024Article
- Neuromodulation by nanozymes and ultrasound during Alzheimer's disease management.Journal of nanobiotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanozymes, a type of nanomaterial with intrinsic enzyme-like activities, have emerged as a promising tool for disease theranostics. As a type of artificial enzyme mimic, nanozymes can overcome the shortcomings of natural enzymes, including high cost, low stability, and difficulty in storage when they are used in disease diagnosis. Moreover, the multi-enzymatic activity of nanozymes can regulate the level of reactive oxygen species (ROS) in various cells. For example, superoxide dismutase (SOD) and catalase (CAT) activity can be used to scavenge ROS, and peroxidase (POD) and oxidase (OXD) activity can be used to generate ROS. In this review, we summarize recent progress on the strategies and applications of nanozyme-based disease theranostics. In addition, we address the opportunities and challenges of nanozyme-based catalytic theranostics in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.